Haemonetics Corporation

Haemonetics Corporation

HAE

$109.34

Updated: 22/09/2026, 16:38:48

Market Cap
$4.97B
Sector
Healthcare
Industry
Medical - Devices
Country
US
Stock valuation chart
One-year closing share-price history for HAE
Company Profile

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

USD
NYSE
CEO: Christopher A. Simon
Employees: 3,009
https://www.haemonetics.com
Asset Summaries
Latest generated summaries for HAE

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for HAE.
Share price
$109.34
Market cap
$4.97B
Exchange
NYSE
Currency
USD
CEO
Christopher A. Simon
Employees
3,009
IPO date
10/05/1991
Beta
0.543
Last dividend
$0.00
Day range
$108.65 – $109.95
52-week range
$47.32 – $110.45
1-day performance
0.56%
1-year performance
131.07%
Current drawdown (1Y)
-1.00%
CIK
0000313143
CUSIP
405024100
ISIN
US4050241003
Created
07/12/2025, 04:28:52
Last update
22/09/2026, 16:38:48

Track Haemonetics Corporation with an AI analyst

See which prediction-market events move HAE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to HAE from your Railway `news_articles` table.

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewsWire • STOCK • 12/06/2026, 09:00:00

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 08/06/2026, 21:18:30

Haemonetics Updates Financial Reporting Segments

PRNewsWire • STOCK • 05/06/2026, 08:30:00

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

PRNewsWire • STOCK • 02/06/2026, 18:05:00

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

Zacks Investment Research • STOCK • 22/05/2026, 12:15:55

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 15:20:51

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut

Zacks Investment Research • STOCK • 11/05/2026, 17:26:26

Haemonetics Q4 Earnings Call Highlights

MarketBeat • STOCK • 10/05/2026, 17:05:21

The London Company Small Cap Portfolio Q1 2026 Portfolio Review

Seeking Alpha • STOCK • 08/05/2026, 07:11:00

Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 08/05/2026, 04:41:17

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Zacks Investment Research • STOCK • 07/05/2026, 10:10:17

Haemonetics to Present at Bank of America 2026 Healthcare Conference

PRNewsWire • STOCK • 05/05/2026, 08:00:00